Literature DB >> 26300678

Nonsurgical treatment of recurrent glioblastoma.

O Gallego1.   

Abstract

Standard treatment for glioblastoma multiforme is surgery followed by radiotherapy and chemotherapy, generally with temozolomide. However, disease recurs in almost all patients. Diagnosis of progression is complex given the possibility of pseudoprogression. The Response Assessment in Neuro-Oncology criteria increase the sensitivity for detecting progression. Most patients will not be candidates for new surgery or re-irradiation, and anticancer drugs are the most common approach for second-line treatment, if the patient's condition allows. Antiangiogenics, inhibitors of the epidermal growth factor receptor, nitrosoureas, and re-treatment with temozolomide have been studied in the second line, but a standard therapy has not yet been established. This review considers currently available medical treatment options for patients with glioblastoma recurrence.

Entities:  

Keywords:  Glioblastoma; chemotherapy; recurrent disease

Year:  2015        PMID: 26300678      PMCID: PMC4530825          DOI: 10.3747/co.22.2436

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  56 in total

1.  Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.

Authors:  M Brada; K Hoang-Xuan; R Rampling; P Y Dietrich; L Y Dirix; D Macdonald; J J Heimans; B A Zonnenberg; J M Bravo-Marques; R Henriksson; R Stupp; N Yue; J Bruner; M Dugan; S Rao; S Zaknoen
Journal:  Ann Oncol       Date:  2001-02       Impact factor: 32.976

2.  Survival and functional status after resection of recurrent glioblastoma multiforme.

Authors:  F G Barker; S M Chang; P H Gutin; M K Malec; M W McDermott; M D Prados; C B Wilson
Journal:  Neurosurgery       Date:  1998-04       Impact factor: 4.654

3.  NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.

Authors:  Roger Stupp; Eric T Wong; Andrew A Kanner; David Steinberg; Herbert Engelhard; Volkmar Heidecke; Eilon D Kirson; Sophie Taillibert; Frank Liebermann; Vladimir Dbalý; Zvi Ram; J Lee Villano; Nikolai Rainov; Uri Weinberg; David Schiff; Lara Kunschner; Jeffrey Raizer; Jerome Honnorat; Andrew Sloan; Mark Malkin; Joseph C Landolfi; Franz Payer; Maximilian Mehdorn; Robert J Weil; Susan C Pannullo; Manfred Westphal; Martin Smrcka; Lawrence Chin; Herwig Kostron; Silvia Hofer; Jeffrey Bruce; Rees Cosgrove; Nina Paleologous; Yoram Palti; Philip H Gutin
Journal:  Eur J Cancer       Date:  2012-05-18       Impact factor: 9.162

4.  Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme.

Authors:  Alessandra B Francesconi; Simon Dupre; Marco Matos; David Martin; Brett G Hughes; David K Wyld; Jason D Lickliter
Journal:  J Clin Neurosci       Date:  2010-06-11       Impact factor: 1.961

5.  Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.

Authors:  David A Reardon; Annick Desjardins; Katherine B Peters; James J Vredenburgh; Sridharan Gururangan; John H Sampson; Roger E McLendon; James E Herndon; April Coan; Stevie Threatt; Allan H Friedman; Henry S Friedman
Journal:  Cancer       Date:  2011-05-16       Impact factor: 6.860

6.  Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.

Authors:  Wolfgang Wick; Vinay K Puduvalli; Marc C Chamberlain; Martin J van den Bent; Antoine F Carpentier; Lawrence M Cher; Warren Mason; Michael Weller; Shengyan Hong; Luna Musib; Astra M Liepa; Donald E Thornton; Howard A Fine
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

7.  BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors.

Authors:  Thomas Reithmeier; Erika Graf; Tobias Piroth; Michael Trippel; Marcus O Pinsker; Guido Nikkhah
Journal:  BMC Cancer       Date:  2010-02-02       Impact factor: 4.430

8.  How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial.

Authors:  A A Brandes; A Tosoni; P Amistà; L Nicolardi; D Grosso; F Berti; M Ermani
Journal:  Neurology       Date:  2004-10-12       Impact factor: 9.910

9.  Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.

Authors:  Jennifer A Quinn; Sara Xiaoyin Jiang; David A Reardon; Annick Desjardins; James J Vredenburgh; Jeremy N Rich; Sridharan Gururangan; Allan H Friedman; Darell D Bigner; John H Sampson; Roger E McLendon; James E Herndon; Amy Walker; Henry S Friedman
Journal:  J Clin Oncol       Date:  2009-02-09       Impact factor: 44.544

10.  Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.

Authors:  Tracy T Batchelor; Paul Mulholland; Bart Neyns; L Burt Nabors; Mario Campone; Antje Wick; Warren Mason; Tom Mikkelsen; Surasak Phuphanich; Lynn S Ashby; John Degroot; Rao Gattamaneni; Lawrence Cher; Mark Rosenthal; Franz Payer; Juliane M Jürgensmeier; Rakesh K Jain; A Gregory Sorensen; John Xu; Qi Liu; Martin van den Bent
Journal:  J Clin Oncol       Date:  2013-08-12       Impact factor: 44.544

View more
  92 in total

Review 1.  CAR T cells and checkpoint inhibition for the treatment of glioblastoma.

Authors:  Steven H Shen; Karolina Woroniecka; Andrew B Barbour; Peter E Fecci; Luis Sanchez-Perez; John H Sampson
Journal:  Expert Opin Biol Ther       Date:  2020-02-17       Impact factor: 4.388

Review 2.  Reactive Astrocytes in Glioblastoma Multiforme.

Authors:  Xiudong Guan; Md Nabiul Hasan; Shelly Maniar; Wang Jia; Dandan Sun
Journal:  Mol Neurobiol       Date:  2018-01-23       Impact factor: 5.590

3.  Acquired temozolomide resistance in human glioblastoma cell line U251 is caused by mismatch repair deficiency and can be overcome by lomustine.

Authors:  J Stritzelberger; L Distel; R Buslei; R Fietkau; F Putz
Journal:  Clin Transl Oncol       Date:  2017-08-20       Impact factor: 3.405

4.  Estimating intratumoral heterogeneity from spatiotemporal data.

Authors:  E M Rutter; H T Banks; K B Flores
Journal:  J Math Biol       Date:  2018-05-08       Impact factor: 2.259

5.  A systematic review of tumor treating fields therapy for high-grade gliomas.

Authors:  Pavan P Shah; Taija White; Adham M Khalafallah; Carlos G Romo; Carrie Price; Debraj Mukherjee
Journal:  J Neurooncol       Date:  2020-06-23       Impact factor: 4.130

6.  Targeting Hyaluronan Interactions for Glioblastoma Stem Cell Therapy.

Authors:  Joline S Hartheimer; Seungjo Park; Shreyas S Rao; Yonghyun Kim
Journal:  Cancer Microenviron       Date:  2019-05-11

7.  pH-Sensitive O6-Benzylguanosine Polymer Modified Magnetic Nanoparticles for Treatment of Glioblastomas.

Authors:  Zachary R Stephen; Rachel N Gebhart; Mike Jeon; Allison A Blair; Richard G Ellenbogen; John R Silber; Miqin Zhang
Journal:  Bioconjug Chem       Date:  2016-12-12       Impact factor: 4.774

8.  Icariside II induces cell cycle arrest and apoptosis in human glioblastoma cells through suppressing Akt activation and potentiating FOXO3a activity.

Authors:  Kai Quan; Xin Zhang; Kun Fan; Peixi Liu; Qi Yue; Bo Li; Jinfeng Wu; Baojun Liu; Yang Xu; Wei Hua; Wei Zhu
Journal:  Am J Transl Res       Date:  2017-05-15       Impact factor: 4.060

9.  Hyaluronic acid induces ROCK-dependent amoeboid migration in glioblastoma cells.

Authors:  Yixiao Cui; Sara Cole; Joel Pepper; José Javier Otero; Jessica O Winter
Journal:  Biomater Sci       Date:  2020-08-04       Impact factor: 6.843

Review 10.  Diagnostic Performance of PET and Perfusion-Weighted Imaging in Differentiating Tumor Recurrence or Progression from Radiation Necrosis in Posttreatment Gliomas: A Review of Literature.

Authors:  N Soni; M Ora; N Mohindra; Y Menda; G Bathla
Journal:  AJNR Am J Neuroradiol       Date:  2020-08-27       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.